Compare Brigit Biofarmaka Teknologi Tbk. (OBAT) vs Temas Tbk. (TMAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brigit Biofarmaka Teknologi Tbk. vs Temas Tbk. — how do they compare? Brigit Biofarmaka Teknologi Tbk. trades at Rp236 (market cap 164.65B, 62.5K 24h volume), while Temas Tbk. trades at Rp127 (market cap 7.36T, 903.4K 24h volume). The key difference: Temas Tbk. is far larger — about 44.7× Brigit Biofarmaka Teknologi Tbk.'s market cap, and Temas Tbk. is more actively traded (903.4K versus 62.5K). Which is the better fit depends on your goals.
| OBAT | TMAS | |
|---|---|---|
Market Cap | 164.65B | 7.36T |
Volume | 62.5K | 903.4K |
Lot | 625 | 9.03K |
Turnover | 15.03M | 115.55M |
Average Price | 240.55 | 127.91 |
Value | 15.03M | 115.55M |
Indicative Equilibrium Price | 238 | 129 |
Indicative Equilibrium Volume | 100 | 11.4K |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Brigit Biofarmaka Teknologi Tbk.
PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Read more on OBAT →About Temas Tbk.
PT Pelayaran Tempuran Emas Tbk (company) was established under the name of PT Tempuran Emas based on Notarial Deed No. 252 dated September 17, 1987 of Misahardi Wilamarta, S.H.The latest amendment of the Articles of Association was registered through Notary Deed No. 26 dated April 14, 2003 of Fathiah Helmi, SH, to comply with the Corporate Law No. 1/1995. The amendment includes, among others, par value of share, increase in capital paid up. The amendment was approved by Ministry of Justice in the Decision Letter No C-08530.HT.01.04.TH.2003 dated 17 April 2003 and was published in the State Gazette No. 49, Supplement No. 4860 dated June 20, 2003.
Read more on TMAS →
